Mivi Neuroscience Names Dr. Waleed Brinjikji as Medical Director

June 7, 2022—Mivi Neuroscience, Inc., a developer of neurointerventional medical devices based in Eden Prairie, Minnesota, announced that Waleed Brinjikji, MD, has joined the company as Medical Director.

As Medical Director, Dr. Brinjikji will provide Mivi with input and medical guidance across a wide spectrum of its activities, including original clinical research and studies, product design and development, and clinical and customer communications.

According to the company, Dr. Brinjikji is an internationally respected interventional neuroradiologist based in Rochester, Minnesota. He is extensively involved in stroke and neuroendovascular research, with > 500 peer-reviewed papers and multiple industry and National Institutes of Health grants, including for a study on improving revascularization techniques in stroke. Most recently, Dr. Brinjikji was Chief Medical Officer of Marblehead Medical, a Minnesota-based stroke company.

“The Mivi team shares my passion for improving the lives of patients who suffer an acute ischemic stroke,” commented Dr. Brinjikji in the company’s press release. “I am looking forward to representing Mivi in the neurointerventional community and contributing to the advancement of novel technologies that advance stroke treatment.”

Bob Colloton, CEO of Mivi Neurovascular, stated in the press release, “We’re looking forward to Dr. Brinjikji joining our team at this exciting time. His insights and experience will be invaluable as we continue to achieve our clinical and commercial milestones for our flagship products, the Q aspiration catheter and DAISe thrombectomy device, and identify new business and development opportunities.”

The company noted that the Q aspiration catheter received European CE Mark approval and is under investigational device exemption in the United States, where it is currently commercially available for distal access. The DAISe thrombectomy device, which is designed to reduce distal embolization and improve patient outcomes, is currently available for investigational use only.